Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | Director | June 10, 2021 | June 11, 2021 |
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director | June 11, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date June 10, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,125 |
Reported balance
After 2021-06-10 transaction · row 1
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 5,125 · Balance 5,125 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2031-06-09 | Direct | 10,250 |
Reported balance
After 2021-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-10 · Grant · Acquired 10,250 · Balance 10,250 F3: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.
F2: Not applicable.
F3: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022).
Janux Therapeutics, Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,750 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 11,750 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10 | Direct | 15,500 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 13, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $13.66 | $0.00 |
DisclosureSEC source: 0001326330-26-000002 · form4-06122026_080601.xml · derivative · entry 2 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2036-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 11, 2026 Filed Jun 13, 2026 00:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001326330-26-000002 · form4-06122026_080601.xml · nonDerivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,750 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $25.46 | $0.00 |
DisclosureSEC source: 0001415889-25-017317 · form4-06132025_070616.xml · derivative · entry 2 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 11,667 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017317 · form4-06132025_070616.xml · nonDerivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 8,350 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-018439 · form4-06282024_040637.xml · derivative · entry 2 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 8,350 shares Expires 2034-06-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018439 · form4-06282024_040637.xml · nonDerivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:06 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037972 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:39 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001209191-22-037453 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:34 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $29.58 | $0.00 |
DisclosureSEC source: 0001209191-21-055341 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-09-06 F1 · shares: The shares subject to the option vest in equal monthly installments over a three year period following September 7, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following September 7, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,250 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-21-039743 · doc4.xml · derivative · entry 2 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Underlying: Common Stock · 10,250 shares Expires 2031-06-09 F3 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022). Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 5,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039743 · doc4.xml · nonDerivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2 · price: Not applicable. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 17:02 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001209191-20-036344 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 11, 2021, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 11, 2021). Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:05 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-19-037563 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 13, 2020. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 18:57 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0000899243-18-017074 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · derivative · entry 9 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · derivative · entry 8 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · derivative · entry 7 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2020-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · derivative · entry 6 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2019-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | SaleCommon Stock | 14,156 | $24.70 | $349,653.20 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · nonDerivative · entry 5 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $2.88 | $10,192.32 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · nonDerivative · entry 4 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $3.50 | $12,386.50 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · nonDerivative · entry 3 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $3.79 | $13,412.81 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · nonDerivative · entry 2 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:48 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $4.41 | $15,606.99 |
DisclosureSEC source: 0001209191-17-064201 · doc4.xml · nonDerivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 07:25 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040704 · doc4.xml · derivative · entry 1 Barrett Ronald W · CIK 0001326330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.